Berenberg analyst Luisa Hector downgraded Roche to Hold from Buy with a price target of CHF 290, down from CHF 320. In context of the Inflation Reduction Act and associated price cuts for large, mature brands, the firm favors companies with strong pipeline momentum and attractive research and development returns. The analyst says Roche lacks pipeline catalysts to unlock value.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Genentech announces ALINA study meets primary endpoint
- Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
- Roche downgraded to Neutral from Buy at BofA
- Capital One says Outlook Therapeutics to receive ‘binary’ FDA decision today
- Roche reports EC approves Evrysdi for babies under two months old with SMA